- Book
- March 2024
- 496 Pages
- Book
- August 2022
- 320 Pages
- Book
- February 2020
- 202 Pages
- Book
- July 2018
- 360 Pages
- Book
- October 2020
- 288 Pages
- Book
- March 2010
- 720 Pages
- Book
- August 2023
Global
- Book
- September 2024
North America
The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more